Business
AZN: Year-To-Date and Q3 2017 Results Announcement
AZN: Year-To-Date and Q3 2017 Results Announcement.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 9871V AstraZeneca PLC 09 November 2017 \n\nAstraZeneca PLC\n9 November 2017 07:00\nYear-To-Date and Q3 2017 Results\nAn improved sales performance as the pipeline-driven transformation gathered pace\n \nFinancial Summary\n\n\n\n\n \n \n\n\nYTD 2017\n\n\nQ3 2017\n\n\n\n\n$m\n\n\n% change\n\n\n$m\n\n\n% change\n\n\n\n\n \n\n\nActual\n\n\nCER1\n\n\nActual\n\n\nCER\n\n\n\n\nTotal Revenue\n\n\n16,688\n\n\n(4)\n\n\n(3)\n\n\n6,232\n\n\n9\n\n\n10\n\n\n\n\nProduct Sales\n\n\n14,665\n\n\n(9)\n\n\n(8)\n\n\n4,882\n\n\n(3)\n\n\n(2)\n\n\n\n\nExternalisation Revenue\n\n\n2,023\n\n\n49\n\n\n50\n\n\n1,350\n\n\nn/m\n\n\nn/m\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nReported Operating Profit\n\n\n2,991\n\n\n26\n\n\n16\n\n\n1,149\n\n\n12\n\n\n9\n\n\n\n\nCore Operating Profit2\n\n\n5,068\n\n\n8\n\n\n5\n\n\n1,853\n\n\n9\n\n\n9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nReported Earnings Per Share (EPS)\n\n\n$1.34\n\n\n3\n\n\n(4)\n\n\n$0.54\n\n\n(32)\n\n\n(33)\n\n\n\n\nCore EPS\n\n\n$2.98\n\n\n(4)\n\n\n(7)\n\n\n$1.12\n\n\n(15)\n\n\n(17)\n\n\n\n\nThe difference in growth rates between Operating Profit and EPS included the impact of a one-off tax benefit in Q3 2016.\n \nFinancial Highlights\n· Receding impact from losses of exclusivity: Product Sales declined by 3% (2% at CER) in the quarter \n· Externalisation Revenue: $2,023m, including $997m received in the quarter from the MSD3 collaboration \n· Cost discipline continued: \n· Reported R&D costs declined by 3% (1% at CER) to $4,206m; Core R&D costs declined by 5% (2% at CER) to $3,956m\n· Reported SG&A costs declined by 11% (9% at CER) to $7,155m; Core SG&A costs declined by 7% (5% at CER) to $5,678m\n· The Company now anticipates a 2017 Core EPS performance towards the favourable end of the guidance range of a low to mid teens percentage decline\n \nCommercial Highlights\nThe Growth Platforms grew by 3% (4% at CER) and represented 66% of Total Revenue:\n· Emerging Markets: 5% growth (7% at CER). China sales in the quarter increased by 12% (14% at CER)\n· Respiratory: 5% ...